CD83 CAR T Cells Overcome CD19 Therapy Resistance
Preclinical research from Roswell Park shows CD83-targeted CAR T cells may address relapse after CD19 CAR T-cell treatment.
Updated on Nov. 17, 2026 in Cancer

Researchers at Roswell Park Comprehensive Cancer Center published a preclinical study in the Journal for ImmunoTherapy of Cancer showing CD83 CAR T cells can overcome resistance to CD19-targeted therapy. A related phase 1 trial, NCT06871410, is enrolling patients with relapsed or treatment-resistant acute myeloid leukemia at Roswell Park.
Why it matters
Median overall survival is poor when disease relapses after CD19 CAR T-cell therapy, which is the standard of care for aggressive B-cell malignancies that have relapsed or are treatment-resistant. Loss of the CD19 antigen can make that therapy ineffective, so an alternative target could matter for patients who run out of options.
The study compared CD83 and CD19 CAR T cells across preclinical models, and CD83 showed low risk of B-cell aplasia, a major cause of non-relapse death after CD19 therapy. Clinical outcomes in patients remain unreported, and the phase 1 trial NCT06871410 is still enrolling.
The players
Roswell Park Comprehensive Cancer Center
A National Cancer Institute-designated comprehensive cancer center in Buffalo, New York, that conducted the study and runs the phase 1 trial.
Moffitt Cancer Center
A Tampa, Florida cancer center that collaborated on the CD83 CAR T research.
University of Minnesota Twin Cities
A public research university whose researchers collaborated on the CD83 CAR T study.
The details
The team evaluated CD83 expression across several B-cell malignancies and found CD83 CAR T was effective as a monotherapy in preclinical models. The work was a collaboration with Moffitt Cancer Center and the University of Minnesota Twin Cities.
Timeline
November 17, 2026: OncLive published an article on the CD83 CAR T preclinical study.
Big Picture
The research builds on CD19 CAR T-cell therapy, which remains the standard of care for relapsed or treatment-resistant aggressive B-cell malignancies. CD83 CAR T is positioned as a follow-on approach for patients whose disease escapes CD19 targeting.
For patients with B-cell cancers that have relapsed after CD19 CAR T-cell therapy, this research points to a possible future option but does not change current treatment today. Patients interested in clinical trial participation can ask oncologists about phase 1 options such as NCT06871410 at Roswell Park.
The takeaway
CD83 CAR T is an early-stage approach, and its value will depend on whether preclinical promise translates into safe, effective responses in patients.
Further reading
For more on related treatment research, see Cancer coverage on Wisevoter.










